Key Financials

Consolidated Key Figures

(thousands of €, if not stated otherwise)		Year ended December 31, 2024		Year ended December 31, 2023
Income statement
Supply revenues		34.863		–
Collaboration revenues		240.786		239.724
Total net revenues		275.649		239.724
Cost of sales		(34.863)		–
R&D expenses		(335.459)		(241.294)
S&M, G&A expenses		(134.438)		(133.965)
Other operating income		40.773		47.272
Operating loss		(188.338)		(88.263)
Net financial results		185.253		93.888
Taxes		1.803		(9.613)
Net loss from continuing operations		(1.282)		(3.988)
Net profit from discontinued operations, net of tax		75.364		215.685
Net profit		74.082		211.696
Income statement from discontinued operations
Product net sales		11.475		112.339
Collaboration revenues		26.041		431.465
Cost of sales		(1.693)		(18.022)
R&D expenses		(8.152)		(190.177)
S&M, G&A expenses		(12.607)		(131.346)
Other operating income		56.180		13.003
Operating profit		71.244		217.262
Net financial results		4.218		499
Taxes		(98)		(2.076)
Net profit from discontinued operations, net of tax		75.364		215.685
Balance sheet
Cash and cash equivalents		64.239		166.803
Financial investments		3.253.516		3.517.698
R&D incentives receivables		172.611		178.688
Assets		4.135.719		4.357.396
Shareholders’ equity		2.896.939		2.795.566
Deferred income		1.071.352		1.327.463
Other liabilities		167.428		234.367
CASH FLOW
Operational cash burn (*)		(373.961)		(414.824)
Cash flow used in operating activities		(320.026)		(405.970)
Cash flow generated from investing activities		220.597		71.186
Cash flow used in financing activities		(4.924)		(5.001)
Decrease in cash and cash equivalents		(104.353)		(339.785)
Effect of currency exchange rate fluctuation on cash and cash equivalents		1.782		(1.522)
Cash and cash equivalents on December 31		64.239		166.810
Cash and cash equivalents from continuing operations		64.239		166.803
Cash and cash equivalents included in assets classified as held for sale		–		7
Financial investments on December 31		3.253.516		3.517.698
Total financial investments and cash and cash equivalents on December 31		3.317.755		3.684.514
FINANCIAL RATIOS
Number of shares issued on December 31		65.897.071		65.897.071
Basic and diluted earnings per share (in €)		1,12		3,21
Share price on December 31 (in €)		26,52		36,99
Total group employees on December 31 (number)(**)		704		1.123

(*)The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

• the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities
• the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in current financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities
• the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.”
  (**) Including in 2023 476 employees related to the discontinued Jyseleca® business